# A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

> **NCT02164955** · — · COMPLETED · sponsor: **Celgene** · enrollment: 775 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IMNOVID

## Key facts

- **NCT ID:** NCT02164955
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-26
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 775 (ACTUAL)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164955, "A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02164955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*